Pathfinders in Biopharma Podcast Por RBC Capital Markets arte de portada

Pathfinders in Biopharma

Pathfinders in Biopharma

De: RBC Capital Markets
Escúchala gratis

OFERTA POR TIEMPO LIMITADO. Obtén 3 meses por US$0.99 al mes. Obtén esta oferta.
Perspectives from the cutting edge of biotech and pharma. The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series. Lead today. Define tomorrow.Copyright 2025 RBC Capital Markets Economía Finanzas Personales Política y Gobierno
Episodios
  • MindMed: Rethinking brain health with psychedelic therapy

    MindMed: Rethinking brain health with psychedelic therapy
    Sep 17 2025

    Over the last 18 months, MindMed has undergone an extraordinary transformation. It released compelling data for its LSD-based drug MM120, followed by FDA breakthrough designation for MM120 for the treatment of GAD, and strong financial backing. CEO Rob Barrow outlines the company's ambitious goals and the path to potentially transforming mental healthcare at RBC's Global Healthcare Conference.
    Más Menos
    12 m
  • Funding the future of retinal health with Eyepoint

    Funding the future of retinal health with Eyepoint
    Sep 3 2025

    Eyepoint CFO George Elston provides insights on the evolving space of retinal disease treatment, focusing on capital allocation, medical innovation, industry engagement and financial prudence.

    Más Menos
    12 m
  • How Blackstone Life Sciences is bridging the innovation gap

    How Blackstone Life Sciences is bridging the innovation gap
    Jul 24 2025

    Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, shares how the firm’s broad life sciences strategy has been advancing innovation across the life sciences ecosystem in three key ways: late-stage product financing (Collaboration) and new company creation (Ownership), and non-dilutive financing (Credit and Royalties). He explains how Blackstone is bridging the innovation funding gap through high-conviction partnerships with larger BioPharma and MedTech companies, and targeted investment in late-stage trials.
    Más Menos
    21 m
Todavía no hay opiniones